BioNTech Investor Day Presentation Deck
Taking mRNA from vision to reality
BNT162b2
BioNTech COVID-19 Va
on vial contains 5 doses a
cular use. Contains no pre
der Emergency Use Autho
EFORE USE.
hours after dilution wher
to 25°C (35 to 77°F).
and time
COMIRNATYⓇ
COVID-19 mRNA Vaccine
First ever approved mRNA therapy¹
Fastest pharma product development and launch
3.4 bn doses administered ²
2 bn to low- and middle-income countries³
> 1 bn individuals vaccinated²
> 175 countries / regions reached
Millions of cases of severe illness or death likely averted4
Trillions of dollars of global economic impact5
1 Authorized or approved for emergency use or temporary use or granted marketing authorization in over 100 countries and regions worldwide, April 2022;
2 As of end April 2022; 3 By end of 2022; 4 Eric C. Schneider et al., The U.S. COVID-19 Vaccination Program at One Year: How Many Deaths and Hospitalizations Were Averted?
(Commonwealth Fund, December 2021). European Centre for Disease Prevention and Control; 5. https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy/
2Pfizer
Pfizer BIONTECH
9View entire presentation